EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

The symptom burden of women with a known risk of breast cancer receiving risk reducing medication

Meagan S Whisenant, Jessica Treviño Jones, Anneliese O Gonzalez, Therese Bartholomew Bevers, Kelly Brassil, Darcy A Ponce, Sharvari Kamat, Emily Solis, Ann Maliackal, Hannah Warlick, Amie Walters, Chloe Denham und 1 weitere

Cancer Treatment and Research Communications · 2025

DOI: 10.1016/j.ctarc.2023.100784 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Treatment and Research Communications, 2025. Verfasst von Meagan S Whisenant und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Behavioral Science, Division of Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, 1515 Holc…. Hauptthemen laut MEDLINE: Breast Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIAMS NIH HHS, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: For the estimated 10 million women in the United States who meet the high-risk criteria for breast cancer, evidence-based interventions may reduce the risk of breast cancer by 50-65 %. Even with substantial evidence supporting preventive medication for risk reduction, there is significant lack of uptake and adherence. The purpose of this study was to characterize the experience of women at high risk for breast cancer and define the content domain for a patient-reported outcomes (PRO) measure of symptom burden from breast cancer risk and risk reducing medication. METHODS: Thirty women at high risk for breast cancer and receiving risk reducing medication participated in single qualitative interviews. Content analysis was used to identify the symptom burden. An expert panel review rated the relevance of symptoms identified in the qualitative interviews to establish the items for inclusion in a PRO symptom burden measure. RESULTS: Participants had a mean age of 54.6 years; 43.3 % self-identified as Hispanic and 20.0 % self-identified as Black. Content analysis found 20 symptoms related to both risk and preventive treatment, with 8 symptoms reported by ≥ 20 % of women. All women described distress related to their risk and preventive care. Treatment-related symptoms varied based on history of risk-reducing surgery and type of endocrine therapy. Women described symptom-related interference with relationships, work, enjoyment of life, and adherence to risk reducing medication. CONCLUSIONS: Women with a known high risk of breast cancer and receiving preventive care experience a unique symptom burden including multiple symptoms and functional impact related to symptoms.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsHumansFemaleMiddle AgedAdultAgedPatient Reported Outcome MeasuresCost of IllnessQualitative ResearchRisk FactorsSymptom Burden

Stichwörter der Autor:innen

Antiestrogen therapyBreast cancerCancer preventionPatient-reported outcomesQuality of lifeSymptoms

Autor:innen und Institutionen

  • Department of Behavioral Science, Division of Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, CPB3.3001, Houston, Texas 77030, USA. Electronic addre…
  • Division of Hematology/Oncology, McGovern Medical School, The University of Texas Health Science Center at Houston, 6431 Fannin, MSB 1.150, Houston, Texas 77030, USA.
  • Department of Clinical Cancer Prevention, Division of Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, 1155 Pressler Street, CPB6.3500, Houston, Texas 77030, USA.
  • Pack Health, a Quest Diagnostics Company, 110 12(th) Street North, Birmingham, Alabama, 35203, USA.
  • Department of Behavioral Science, Division of Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, CPB3.3001, Houston, Texas 77030, USA.
  • Department of Research, Cizik School of Nursing, The University of Texas Health Science Center at Houston, 6901 Bertner Avenue, Houston, Texas 77030, USA.

Förderung

  • NIAMS NIH HHS
  • National Institute of Arthritis and Musculoskeletal and Skin Diseases
  • National Institutes of Health

Zitieren

APA

Whisenant, M. S., Jones, J. T., Gonzalez, A. O., Bevers, T. B., Brassil, K., Ponce, D. A., Kamat, S., Solis, E., Maliackal, A., Warlick, H., Walters, A., Denham, C., & Williams, L. A. (2025). The symptom burden of women with a known risk of breast cancer receiving risk reducing medication. Cancer Treatment and Research Communications. https://doi.org/10.1016/j.ctarc.2023.100784

Vancouver

Whisenant MS, Jones JT, Gonzalez AO, Bevers TB, Brassil K, Ponce DA, et al. The symptom burden of women with a known risk of breast cancer receiving risk reducing medication. Cancer Treatment and Research Communications. 2025. doi:10.1016/j.ctarc.2023.100784

BibTeX
@article{Whisenant2025,
  author = {Whisenant, Meagan S and Jones, Jessica Treviño and Gonzalez, Anneliese O and Bevers, Therese Bartholomew and Brassil, Kelly and Ponce, Darcy A and Kamat, Sharvari and Solis, Emily and Maliackal, Ann and Warlick, Hannah and Walters, Amie and Denham, Chloe and Williams, Loretta A},
  title = {The symptom burden of women with a known risk of breast cancer receiving risk reducing medication},
  journal = {Cancer Treatment and Research Communications},
  year = {2025},
  doi = {10.1016/j.ctarc.2023.100784}
}
Kostenlos starten →